Tenax Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TENX research report →
Range $4 – $5
Price Chart
About the company
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials.
- CEO
- Christopher T. Giordano
- IPO
- 1994
- Employees
- 15
- HQ
- Chapel Hill, NC, US
Get TickerSpark's AI analysis on TENX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $33.16M
- P/E
- -0.99
- PEG
- 0.04
- P/S
- 0.00
- P/B
- 0.68
- EV/EBITDA
- 1.13
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -60.61%
- ROIC
- -63.99%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-56,385,000
- Net Income
- $-52,599,000-198.8%
- EPS
- $-1.34-16.5%
- OCF Growth
- -141.7%
- FCF Growth
- -141.7%
- 52W High
- $19.40
- 52W Low
- $1.24
- 50D MA
- $1.75
- 200D MA
- $9.18
- Beta
- 0.97
- RSI (14)
- 28
- Avg Volume
- 3.18M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tenax said LEVO-CTS missed its primary endpoints, but management sees clinically meaningful signals in subgroups and plans to pursue an NDA based on existing data.· March 21, 2017
- LEVO-CTS did not meet the dual or quad primary endpoints, but did show statistically significant improvements in 2 of 3 secondary endpoints.
- Management highlighted a 35% mortality reduction at 90 days overall, and stronger subgroup trends in bypass-only patients, including 67% lower mortality at 30 days and 73% lower mortality at 90 days.
- The company plans a pre-NDA meeting with the FDA in the second quarter to discuss Levosimendan for acute decompensated heart failure and possible cardiac surgery filings.
- Cash at year-end was $21.9 million, and management said existing capital should fund operations through the first half of 2018.
- Tenax said it will engage an investment bank to explore strategic options and broaden the product line.
For the year ended December 31, 2016, Tenax reported a net loss of $43.9 million, or $1.56 per share, versus a net loss of $15.9 million, or $0.57 per share, in 2015. Total operating expenses were $52.7 million, up from $16.6 million, driven mainly by a $33.3 million impairment loss tied to the Phase 3 LEVO-CTS trial and about $4.2 million higher R&D spending. Research and development expense was approximately $13.1 million versus $8.9 million a year earlier, while G&A was $6.2 million versus $6.7 million. Cash and cash equivalents plus marketable securities were $21.9 million at December 31, 2016, down from $38.2 million a year earlier. Management expects significant decreases in quarterly R&D expense in the first half of 2017 as LEVO-CTS closeout work is completed, anticipates full-year G&A of $5 million to $5.5 million, and said there are no committed R&D costs beyond current closeout activities; it believes cash is sufficient through the first half of 2018.
John Kelley framed the quarter around the full LEVO-CTS dataset and emphasized that, although the study missed its primary endpoints, the drug showed meaningful clinical activity in secondary measures and subgroup analyses. He pointed to reduced low-cardiac-output syndrome, lower use of secondary inotropes, improved cardiac index, and a favorable safety profile with no serious adverse events observed. His tone was cautiously optimistic, saying the company will continue evaluating Levosimendan in cardiac surgery and other cardiac indications and will discuss the best NDA path with the FDA.
Michael Jebson focused on the year-over-year financial deterioration driven largely by a $33.3 million impairment charge and higher trial-related R&D. He noted R&D rose to approximately $13.1 million from $8.9 million, while G&A declined to $6.2 million from $6.7 million, and said cash and marketable securities totaled $21.9 million at year-end. He guided to lower near-term R&D spending as LEVO-CTS closes out, full-year G&A of $5 million to $5.5 million, and stated the company believes it has enough capital to operate through the first half of 2018.
Analysts pressed on cash burn, the role of Health Canada versus the FDA, and whether blood-pressure management could have improved outcomes in the trial. Management said most of the remaining 2017 R&D spend will be about $2.5 million for LEVO-CTS closeout, with second-half R&D dependent on strategy, and said there are no committed R&D costs today. On regulatory path, management said it plans to pursue an NDA based on existing data and does not think another study is necessary, while noting Health Canada may weigh European precedent differently than the FDA.
The positive case from this call is that Levosimendan showed repeated signals of activity despite missing the primary endpoints, including improvements in key secondary endpoints and a safety profile with no serious adverse events. Management also pointed to strong subgroup mortality trends in bypass-only patients and said it plans to seek regulatory feedback on NDA options using existing data.
The main risk is that LEVO-CTS missed both primary endpoints, which weakens the case for broad approval and leaves the results open to regulatory skepticism. There was also a concerning signal in patients with valve procedures, where management said Levosimendan appeared to have a negative effect on mortality, and the company’s strategy still depends on FDA feedback and strategic alternatives rather than a clear commercial path.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 26.53M
- Float Shares
- 26.47M
of shares held by institutions
129 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Adar1 Capital Management, LLC | 6.52M | ▲ 6.30M |
| Blackrock, Inc. | 2.81M | ▲ 1.08M |
| Vivo Capital, LLC | 2.50M | 0 |
| Sphera Funds Management Ltd. | 2.32M | ▲ 2.20M |
| Janus Henderson Group Ltd. | 1.82M | ▲ 1.65M |
| Marshall Wace, Llp | 1.78M | ▲ 1.19M |
| Perceptive Advisors LLC | 1.70M | ▲ 252.22K |
| Millennium Management LLC | 1.36M | ▲ 486.50K |
| Aqr Capital Management LLC | 1.25M | ▲ 1.25M |
| Vanguard Capital Management LLC | 1.13M | ▼ 15.15K |
| Morgan Stanley | 942.94K | ▲ 510.72K |
| Geode Capital Management, LLC | 864.60K | ▲ 225.06K |
Held by 89 ETFs
Biggest fund positions in TENX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 21, 26 | ADAR1 Capital Management, LLC | buy | 331,979 |
| Oct 20, 26 | ADAR1 Capital Management, LLC | buy | 254,342 |
| Oct 19, 26 | ADAR1 Capital Management, LLC | buy | 336,528 |
| Sep 16, 26 | Doogan Declan | buy | 53,000 |
| Sep 15, 26 | Giordano Christopher Thomas | buy | 4,850 |
| Sep 11, 26 | Giordano Christopher Thomas | buy | 6,000 |
| Sep 11, 26 | STAAB THOMAS R II | buy | 5,675 |
| Sep 3, 26 | ADAR1 Capital Management, LLC | buy | 900,000 |
| Sep 2, 26 | ADAR1 Capital Management, LLC | buy | 187,704 |
| Sep 1, 26 | ADAR1 Capital Management, LLC | buy | 179,058 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TENX coverage
Recent articles, reports, and earnings notes.
No research on TENX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TENX report →ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
newsfilecorp.com · Nov 20
What Should Tenax Therapeutics, Inc. Investors Know After 89.77% Stock Drop? The Law Offices of Frank R.
prnewswire.com · Nov 20
Kaplan Fox Alerts Investors to a Deadline for a Securities Fraud Class Action Lawsuit Against Tenax Therapeutics, Inc. (TENX) on December 28, 2026
newsfilecorp.com · Nov 20
ROSEN, A LEADING NATIONAL FIRM, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
newsfilecorp.com · Nov 19
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
globenewswire.com · Nov 19
DEADLINE ALERT for Tenax Therapeutics, Inc. (TENX), Everest Group, Ltd. (EG), and Lululemon Athletica, Inc (LULU): The Law Offices of Howard G.
globenewswire.com · Nov 19
DEADLINE ALERT for UP Fintech Holding Limited (TIGR), Tenax Therapeutics, Inc. (TENX), Everest Group, Ltd. (EG), and Yiren Digital Ltd.
globenewswire.com · Nov 19
TENAX THERAPEUTICS, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs Tenax Therapeutics, Inc. (TENX) Investors of a Securities Fraud Lawsuit
newsfilecorp.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.